Comparative Pharmacology
Head-to-head clinical analysis: EXELON versus RAZADYNE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXELON versus RAZADYNE ER.
EXELON vs RAZADYNE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exelon (rivastigmine) is a reversible, non-competitive acetylcholinesterase and butyrylcholinesterase inhibitor, increasing acetylcholine levels in the brain.
Reversible, competitive acetylcholinesterase inhibitor, increasing acetylcholine concentrations in the synaptic cleft of the central nervous system, particularly enhancing cholinergic neurotransmission in the cerebral cortex and hippocampus.
Initial: 1.5 mg orally twice daily; after 2 weeks increase to 3 mg twice daily; then after 2 weeks increase to 4.5 mg twice daily; then after 2 weeks increase to 6 mg twice daily (maximum). For transdermal patch: initial 4.6 mg/24 hr applied once daily; after 4 weeks increase to 9.5 mg/24 hr; may increase to 13.3 mg/24 hr after additional 4 weeks.
16 mg orally once daily in the morning; may increase to 24 mg once daily after minimum of 4 weeks; maximum dose 24 mg/day.
None Documented
None Documented
Terminal half-life: ~1.5 hours; clinical context: tid dosing recommended due to rapid elimination.
Terminal half-life approximately 7-8 hours; clinical context: supports twice-daily dosing
Renal (97%) with unchanged drug <1%; biliary/fecal as metabolites.
Renal: 95% as unchanged drug and metabolites; Fecal: 5%
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor